BioMed Research International

BioMed Research International / 2015 / Article

Research Article | Open Access

Volume 2015 |Article ID 318306 |

Mark Dzietko, Maria Hahnemann, Oliver Polley, Marco Sifringer, Ursula Felderhoff-Mueser, Christoph Bührer, "Effects of PMA (PHORBOL-12-MYRISTATE-13-ACETATE) on the Developing Rodent Brain", BioMed Research International, vol. 2015, Article ID 318306, 9 pages, 2015.

Effects of PMA (PHORBOL-12-MYRISTATE-13-ACETATE) on the Developing Rodent Brain

Academic Editor: Limei Qiu
Received11 Dec 2014
Accepted13 Mar 2015
Published30 Mar 2015


Perinatal infections have a negative impact on brain development. However, the underlying mechanisms leading to neurological impairment are not completely understood and reliable models of inflammation are urgently needed. Using phorbol-myristate-acetate as an activator of inflammation, we investigated the effect on the developing rodent brain. Neonatal rats and mice deficient in IL-18 or IRAK-4 were exposed to PMA. Brains were assessed for regulation of pro- and anti-inflammatory cytokines and cell death 24 hrs, 7 and 14 days after treatment. PMA induced an inflammatory response and caused widespread neurodegeneration in the brains of 3- and 7-day-old rats. In contrast, 14-day-old rats were resistant to the neurotoxic effect of PMA. Histological evaluation at the age of 14 and 21 days revealed a destruction of the cortical microstructure with decreased numerical density of neuronal cells. Mice deficient in IL-18 or IRAK-4 were protected against PMA induced brain injury. PMA treatment during a vulnerable period can alter brain development. IL-18 and IRAK-4 appear to be important for the development of PMA induced injury.

1. Introduction

Recent advances in the understanding of fetal physiology and neonatal intensive care medicine have resulted in markedly increased survival rates of premature infants. However, severe motor and cognitive impairment still affects a considerable proportion of surviving patients, who exhibit disturbances in learning, cognition, and attention [1]. Whereas many of these disabilities have been attributed mostly to white matter injury, disrupted grey matter development also appears to contribute to disabilities of preterm survivors [2]. Brain injury with widespread loss of neurons has been noted in the cortex, hippocampus, and thalamus of postmortem specimens from patients with periventricular leukomalacia (PVL) [3]. However, the pathology of perinatal brain injury is complex and depends on injury mode and developmental stage [4]. Over the last decade the hypoxic-ischemic paradigm for neonatal brain injury has been replaced by a multifactorial hypothesis which recognizes the key role elevated levels of proinflammatory cytokines play in systemic inflammation of the brain [5]. In previous studies, we induced inflammation by hyperoxia in combination with lipopolysaccharide (LPS) and identified the role of inflammatory cytokines in neurodegenerative processes in the developing brain [6, 7]. These inflammatory mediators trigger strong alterations in brain development and changes in microstructural integrity [7]. Furthermore, an increase in degenerating cells in the thalamus of newborn rabbits prenatally exposed to endotoxins suggests impairment of grey matter [8].

T-cell activation is a fundamental step for an effective immune response and is triggered by the interaction of receptors to specific ligands with concomitant formation of diacylglycerol and activation of protein kinase C (PKC). PMA, a structural analogue of diacylglycerol, is a potent activator of PKC [9]. Activation of PKC by PMA results in the induction of granulocytes, proinflammatory cytokines like IL-6, TNF-α, IL-1β, increased levels of glutamate, and the release of reactive oxygen species [10, 11]. In the developing rodent brain, IL-1β and IL-18 play a pivotal role in inflammatory responses with subsequent cell death [6, 7, 12]. Engagement of IL-1β and IL-18 receptors initiates a common intracellular signaling cascade wherein the myeloid differentiation factor (MyD88) and TNF receptor associated factor 6 (TRAF6) serve as key adaptor proteins. It has been shown that IRAK-4 mediates signaling between MyD88 and TRAF6 thereby providing an essential component in promoting downstream signals. Nevertheless the complex mechanisms of inflammation leading to brain injuries are still controversial and remain unclear. Seeking to better understand the histological injury patterns and pathways involved in inflammatory neonatal brain injuries, we applied PMA as an inflammatory trigger to neonatal rodents. By administering PMA to IRAK-4 and IL-18 knockout mice we provide additional evidence that disruption of inflammatory pathways is sufficient to protect the developing brain from PMA induced injury.

2. Materials and Methods

2.1. Animals and Drug Administration

All animal experiments were carried out in accordance with institutional guidelines and conform to the European Guidelines for Use of Experimental Animals by FELASA (Federation of European Laboratory Animal Science Association) and were approved by the local animal research committee. 2-, 6- and 13-day-old randomly assigned male Wistar rat pups (BgVV, Berlin, Germany) received a single intraperitoneal (i.p.) injection of vehicle (normal saline, Braun, Ingelheim, Germany) or PMA (500 μg/kg, Sigma, St. Louis, USA). A subgroup of 6-day-old rat pups received a single injection of vehicle or different PMA doses (100, 200, and 500 μg/kg). Animals were sacrificed 24 hours or 7 and 14 days following PMA exposure.

6-day-old homozygous IRAK-4-deficient C57BL/6 mice (provided by Dr. Yeh, Ontario Cancer Institute, Toronto, Canada) and Interleukin-18-deficient C57BL/6 mice (B6.129P2-Il18tm1Aki/J, Jackson Laboratory, Bar Harbor, USA) received a single injection of PMA (200 μg/kg). Wild-type mice serving as controls received either PMA or vehicle. All pups were kept with their dams except for injections to avoid hypothermia and malnutrition.

2.2. Tissue Sampling

Animals subjected to histological analysis received an overdose of chloral-hydrate and were transcardially perfused with 0.1 M phosphate-buffered saline followed by 4% paraformaldehyde in cacodylate buffer solution. Coronal paraffin sections (10 μm, microtome HM 360; Microm, Giessen, Germany) were stained with cresyl violet to determine total cell density in P14 and P21 animals. For real-time PCR analysis, animals were decapitated, brains were immediately removed, and hemispheres were snap frozen in liquid nitrogen and stored at −80°C until analysis.

2.3. RNA Extraction and Semiquantitative Real-Time PCR

Total RNA was isolated from snap-frozen tissue by acidic phenol/chloroform extraction (peqGOLD RNAPure; PEQLAB Biotechnologie, Erlangen, Germany) and 2 μg of RNA was reverse transcribed. The PCR products of IL-1β, TNF-α, TGF-β1, and hypoxanthine-guanine phosphoribosyltransferase (HPRT, as internal standard) were quantified in real time, using dye-labeled fluorogenic reporter oligonucleotide probes and primers (Metabion, Munich, Germany) with the following sequences and corresponding GenBank accession numbers: IL-1β (NM_031512) sense 5′-AACAAAAATGCCTCGTGCTGTCT-3′, antisense 5′-TGTTGGCTTATGTTGTGTCCATTG-3′, probe 5′-ACCCATGTGAGCTGAAAGCTCTCC-3′; TNF-α (NM_012675) sense 5′-TCGAGTGACAAGCCCGTAGC-3′, antisense 5′-CTCAGCCACTCCAGCTGCTC-3′, probe 5′-CGTCGTAGCAAACCACCAAGCAGA-3′; TGF-β1 (NM_021578) sense 5′-CCCTGCCCCTACATTTGGA-3′, antisense 5′-ACGGTGATGCGGAAGCAC-3′, probe 5′-CACACAGTACAGCAAGGTCCTTGCCCT-3′; HPRT (NM_012583) sense 5′-GGAAAGAACGTCTTGATTGTTGAA-3′, antisense 5′-CCAACACTTCGAGAGGTCCTTTT-3′, probe 5′-CTTTCCTTGGTCAAGCAGTACAGCCCC-3′. All probes were labeled at their 5′ ends with the reporter dye 6-carboxy-fluoresceine (FAM) and at their 3′ ends with the quencher dye 6-carboxy-tetramethylrhodamine (TAMRA). Real-time PCR and detection were performed in triplicate and repeated 3 times for each sample using a total reactive volume of 13 μL which contained 6.5 μL of 2x TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, USA), 2.5 μL of 1.25 μM oligonucleotide mix, 0.5 μL (0.5 μM) of probe, and 50 ng of cDNA template. The PCR amplification was performed in 96-well optical reaction plates for 40 cycles with each cycle at 94°C for 15 s and 6°C for 1 min. The expression of IL-1β, TNF-α, TGF-β1, and HPRT was analyzed with the real-time PCR ABI Prism 7500 sequence detection system (Applied Biosystems) according to the method [13].

2.4. De Olmos Cupric Silver Staining

Brains were embedded in agar; coronal sections (70 μm) were cut and processed for staining with silver and cupric nitrate according to the method of De Olmos and Ingram [14]. Degenerating cells were identified by a distinct dark appearance due to silver impregnation.

2.5. Fluoro-Jade B Staining

Paraffin sections were incubated for 10 min in 0.06% solution of potassium permanganate and stained for 20 min in 0.0004% solution of fluoro-jade B (Histo-Chem, Jefferson, USA) dissolved in 0.1% acetic acid. Sections were coverslipped with nonfluorescent mounting media (Sigma) and samples were examined with an epifluorescent microscope using blue light (excitation 450–490 nm, emission 515–565 nm). Degenerating cells were identified by a green fluorescent appearance.

2.6. TUNEL Staining

Staining was performed on paraffin sections using the Apop Tag Peroxidase kit (Oncor Appligene, Heidelberg, Germany) according to the manufacturer’s instructions. Sections were finally stained with diaminobenzidine (Sigma) and TUNEL positive cells were identified by brown appearance.

2.7. Immunohistochemistry for Cleaved Caspase-3

Paraffin sections were microwaved in 10 mM citrate buffer and endogenous peroxidase activity was blocked with 0.6% hydrogen peroxide. Slices were incubated with normal goat serum overnight at 4°C with anti-cleaved caspase-3 antibody (1 : 100; Cell Signaling, Frankfurt, Germany). Sections were treated with rabbit anti-goat IgG. After detection with ABC kit (Vector Laboratories, Peterborough, UK), positive cells were visualized with diaminobenzidine.

2.8. Quantification of Neurodegeneration

Degenerating cells were identified by using De Olmos, cresyl violet (rat), or fluoro-jade B staining (mice). Mean numerical cell densities () of degenerating cells or total cell density (cells/mm3) were acquired in 17 brain regions by means of a stereological dissector. An unbiased counting frame (0.05 × 0.05 mm, dissector height 0.01 mm for fluoro-jade B/cresyl violet, 0.07 mm for silver staining) and a high aperture objective were used for sampling. Numerical densities () within each brain region for cell degeneration or total cell density were determined with eight dissectors [15]. The generated cumulative score for each animal was used for comparison.

2.9. Statistical Analyses

Values are presented as mean ± SEM. Comparisons among groups were made using one-way analysis of variance (ANOVA) with Newman-Keul post hoc test or Student’s -test as appropriate. Statistical significance was determined at .

3. Results

3.1. PMA Exposure Affects Postnatal Weight Gain

Han Wistar rats treated with PMA (500 μg/kg) showed impaired weight gain compared to control littermates. Average weight gain was significantly reduced in animals 7 and 14 days old. Animals receiving a lower dose or are 3 days old showed adequate weight gain. Survival rate was not altered within treatment groups (Table 1).



Average weight gain
1.0 ± 0.21.3 ± 0.11.0 ± 0.21.4 ± 0.21.3 ± 0.21.4 ± 0.20.5**  ±  0.11.4 ± 0.20.7***  ±  0.12.8 ± 0.2

% survival1001008810010010091100100100


P7 and P14 rats treated with PMA 500 g/kg showed impaired weight gain 24 hours after injection compared to their control littermates (±SEM, ; , Student’s -test).
3.2. PMA Triggers mRNA Expression of IL-1β

To determine how the proinflammatory cytokines IL-1β and TNF-α and the anti-inflammatory cytokine TGF-β1 were affected by PMA exposure in the neonatal brain, we performed real-time polymerase chain reaction (PCR) on mRNA isolated from brain hemispheres obtained 24 hours after exposure. Quantitative analysis of mRNA expression revealed a significant increase of IL-1β (Figure 1(a)) after PMA exposure (500 μg/kg). TNF-α and TGF-β1 expression was not affected by PMA therapy (Figures 1(b) and 1(c)). Control animals and pups treated with a lower dose (200 μg/kg) exhibited no modification of cytokine expression (Figures 1(a)1(c)).

3.3. PMA Induces a Robust Neurodegenerative Response in the Immature Brain

To explore whether a single injection of PMA exerted neurodegenerative effects, P6 rat pups were exposed to 500 μg/kg PMA. Histological stainings revealed widespread neurodegeneration (Figures 2(b), 2(d), 2(f), and 2(h)). In age-matched littermates receiving vehicle, degenerating cells were sparse (Figures 2(a), 2(c), 2(e), and 2(g)). Fluoro-jade B, TUNEL, and caspase-3 staining showed a similar distribution pattern of degenerating cells compared to silver staining, suggesting apoptosis as a mechanism of PMA induced cell death. The primary affected brain regions were the second layer of the cortex, thalamus, and hypothalamus, as depicted in Figure 3.

3.4. High Dose PMA Induces Neurodegeneration in the Developing Brain

To Investigate the effects of different doses of PMA on the immature brain 6-day-old rats were treated with 100, 200, or 500 μg/kg PMA. Animals treated with lower doses of PMA were indistinguishable from control animals. However, profound neurodegeneration was confirmed after treatment with 500 μg/kg PMA (Figure 4).

3.5. PMA-Induced Neurodegeneration Is Age Dependent

To determine whether the apoptotic response to PMA may differ as a function of developmental age, we subjected 2-, 6-, and 13-day-old rats to PMA (500 μg/kg). P3 and P7 animals exposed to PMA revealed enhanced neurodegeneration in comparison to controls suggesting a time window between P3 and P7 when neuronal cells are vulnerable to PMA-induced cell death. In contrast, P14 rats showed no significant difference after treatment with PMA in comparison to controls (Figure 5).

3.6. Neonatal PMA Exposure Reduces Neuronal Cell Density in the Adolescent Rat

In order to investigate whether neonatal exposure to PMA diminishes the total amount of neuronal cells and affects cortical cytoarchitecture in older animals, we administered PMA to 6-day-old rats. Histological evaluation with cresyl violet staining at the age of 14 and 21 days revealed a destruction of the cortical microstructure (Figures 6(a) and 6(b)), with a decreased numerical density of neuronal cells (Figure 6(c)). The cytoarchitecture in animals exposed to PMA as a neonate was disorganized, lacking the expected arrangement of neurons on columns typically seen in the normal neocortex. These results suggest a long-lasting effect on brain development by PMA exposure early in life.

3.7. Mice Deficient in IRAK-4 and IL-18 Are Protected against PMA-Induced Cell Death

To confirm a functional contribution of IL1-β and IL-18 in PMA-induced cell death, we injected PMA (200 μg/kg) to 6-day-old IRAK-4 and IL-18 knockout mice. Wild-type mice treated with PMA or vehicle served as controls. Mice receiving a higher dose of PMA (500 μg/kg) did not survive suggesting a higher sensitivity of mice to PMA. Brains were processed for fluoro-jade B staining 24 hours later to detect neuronal injury. PMA caused neuronal cell death in the wild-type mice with a pattern very similar seen in rats. Vehicle treated wild-type animals revealed a significant difference compared to PMA treated littermates. Quantification of cell death in IRAK-4 and IL-18 knockout mice after PMA exposure displayed a strong neuroprotective effect compared to PMA treated wild-type controls (Figure 7).

4. Discussion

Here we describe an activation of the proinflammatory cytokine IL-1β and a strong neurodegenerative response in neonatal rodents after systemic PMA exposure. A single injection of PMA was sufficient to double the amount of degenerating cells. The injury pattern was confirmed in different histological stainings suggesting programmed cell death as a major component of the injury. Impairment of weight gain seems not to play a pivotal role in PMA induced neurotoxicity because older animals were not affected despite the fact that weight gain was significantly depressed. Furthermore, we found the neurotoxic effect of PMA to be confined to the first postnatal week of life. The first postnatal week of life is characterized by rapid brain growth and these results confirm the vulnerability of the neonatal brain during this growth spurt [16]. PMA treatment predominantly affected the second cortical layer and the laterodorsal thalamus but all investigated areas exhibited degenerated cells. Prenatal endotoxin exposure in rabbits revealed similar results with a profound decrease of neurons in the anterior thalamus [8]. In addition, neurodegeneration in the thalamus is combined with a decrease of dendritic arborization in the retrosplenial cortex suggesting an increased vulnerability of this important relay station [8].

From human data, it is known that the thalamus is commonly affected in patients with cerebral palsy, and atrophy of deep grey matter has previously been described in patients with PVL [2]. This contrasts to hypoxia-ischemia in a preterm ovine model, which also revealed an immature dendritic arborization without detected neuronal cell death, underlining the specific role of inflammation in neonatal brain injury and the importance of the mode of injury [17]. Interestingly, animals treated with PMA had a lower total density of neuronal cells with transformation of the cortical microarchitecture 14 and 21 days after birth. Normal cortex exhibits a specific cytoarchitecture and is horizontally organized into laminae and vertically into groups of synaptically linked cells, called neocortical minicolumns. This represents the basic processing units of the mature neocortex [18]. The cortical cytoarchitecture in animals treated with PMA early in life was disorganized, primarily affecting layer II by disrupting the expected arrangement of cells in layers and columns. Analog to our results, inflammation during the critical period of brain development induced by LPS leads to amplified neuronal injury and impairment of synaptic plasticity [19]. Furthermore, neonatal exposure of LPS and oxygen revealed decreased numbers of oligodendrocytes in the adult cortex and hippocampus [20].

PMA has been described to activate granulocytes, to elevate levels of proinflammatory cytokines like IL-6, TNF-α, and IL-1β, and to release reactive oxygen species and glutamate as potential mechanisms of injury [10, 11, 21]. In our model, we also found a strong increase of IL-1β as a response after PMA exposure, supporting the idea of using PMA as an activator for a systemic inflammatory response. In addition, we used IRAK-4 and IL-18 knockout mice to further address possible mechanisms involved in PMA induced neurotoxicity. IRAK-4 is required for LPS-induced activation of antigen presenting cells with IRAK-4-deficient animals being completely resistant to LPS [22, 23]. Furthermore, animals inhibited or deficient for IRAK-4 are protected against oxygen-mediated [6] and hypoxia-ischemia (HI) induced neuronal injury [24]. In our experiments IRAK-4 knockout mice treated with PMA were protected compared to their wild-type littermates. These results suggest that PMA treatment does promote IRAK-4 mediated neurodegeneration. An inflammatory role for IL-18 has been implicated in several diseases including HI in the immature brain. IL-18 is increased after HI and IL-18 deficiency has also been shown to be protective against brain injury after neonatal HI [25, 26]. In contrast, adult mice lacking the gene for IL-18 are not protected against ischemic injury emphasizing the controversy regarding the role of IL-18 in different injury models and developmental stages [27]. In our studies, mice deficient for IL-18 were protected against PMA toxicity suggesting a potential role of IL-18 in PMA triggered brain injury.

5. Conclusions

To our knowledge, this is the first study showing that systemic PMA application during a critical period of development can induce an inflammatory response combined with neurodegeneration and alter brain development with long-lasting effects into adolescence. The injury is characterized by diffuse grey matter injury with programmed cell death being a component involved in neuronal injury. IRAK-4 and IL-18, two major inflammatory pathways, seem to be involved in PMA triggered brain injury. The increasing problem of diffuse brain injury [28] raises in our opinion the need for more subtle models of inflammation triggered brain injury.

Conflict of Interests

The authors declare that there is no conflict of interests with any financial organization regarding the commercial identities mentioned in the paper.


This work was supported by grants from the Metzler-Stiftung, Frankfurt, Germany, the European Commission (Sixth Framework Program, LSHM-CT-2006-036534), the Swiss National Fund N° 31003A-112233, the Centre d’Imagerie Biomédicale of the UNIL (L’Université de Lausanne), UNIGE (University of Geneva), HUG (Geneva University Hospitals), CHUV (Centre Hospitalier Universitaire Vaudois), and EPFL (École Polytechnique Fédérale de Lausanne) and the Leenards and Jeantet foundations.


  1. M. Hack, D. J. Flannery, M. Schluchter, L. Cartar, E. Borawski, and N. Klein, “Outcomes in young adulthood for very-low-birth-weight infants,” The New England Journal of Medicine, vol. 346, no. 3, pp. 149–157, 2002. View at: Publisher Site | Google Scholar
  2. G. Ball, J. P. Boardman, D. Rueckert et al., “The effect of preterm birth on thalamic and cortical development,” Cerebral Cortex, vol. 22, no. 5, pp. 1016–1024, 2012. View at: Publisher Site | Google Scholar
  3. S. E. Andiman, R. L. Haynes, F. L. Trachtenberg et al., “The cerebral cortex overlying periventricular leukomalacia: analysis of pyramidal neurons,” Brain Pathology, vol. 20, no. 4, pp. 803–814, 2010. View at: Publisher Site | Google Scholar
  4. M. Ajayi-Obe, N. Saeed, F. M. Cowan, M. A. Rutherford, and A. D. Edwards, “Reduced development of cerebral cortex in extremely preterm infants,” The Lancet, vol. 356, no. 9236, pp. 1162–1163, 2000. View at: Publisher Site | Google Scholar
  5. A. Pappas, D. E. Kendrick, S. Shankaran et al., “Chorioamnionitis and early childhood outcomes among extremely low-gestational-age neonates,” JAMA Pediatrics, vol. 168, no. 2, pp. 137–147, 2014. View at: Publisher Site | Google Scholar
  6. U. Felderhoff-Mueser, M. Sifringer, O. Polley et al., “Caspase-1-processed interleukins in hyperoxia-induced cell death in the developing brain,” Annals of Neurology, vol. 57, no. 1, pp. 50–59, 2005. View at: Publisher Site | Google Scholar
  7. F. Brehmer, I. Bendix, S. Prager et al., “Interaction of inflammation and hyperoxia in a rat model of neonatal white matter damage,” PLoS ONE, vol. 7, no. 11, Article ID e49023, 2012. View at: Publisher Site | Google Scholar
  8. B. Balakrishnan, H. Dai, J. Janisse, R. Romero, and S. Kannan, “Maternal endotoxin exposure results in abnormal neuronal architecture in the newborn rabbit,” Developmental Neuroscience, vol. 35, no. 5, pp. 396–405, 2013. View at: Publisher Site | Google Scholar
  9. G. Goel, H. P. S. Makkar, G. Francis, and K. Becker, “Phorbol esters: structure, biological activity, and toxicity in animals,” International Journal of Toxicology, vol. 26, no. 4, pp. 279–288, 2007. View at: Publisher Site | Google Scholar
  10. E. Kontny, M. Ziólkowska, A. Ryzewska, and W. Maśliński, “Protein kinase C-dependent pathway is critical for the production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6),” Cytokine, vol. 11, no. 11, pp. 839–848, 1999. View at: Publisher Site | Google Scholar
  11. A. G. Thomas, C. M. O'Driscoll, J. Bressler, W. Kaufmann, C. J. Rojas, and B. S. Slusher, “Small molecule glutaminase inhibitors block glutamate release from stimulated microglia,” Biochemical and Biophysical Research Communications, vol. 443, no. 1, pp. 32–36, 2014. View at: Publisher Site | Google Scholar
  12. U. Felderhoff-Mueser, O. I. Schmidt, A. Oberholzer, C. Bührer, and P. F. Stahel, “IL-18: A key player in neuroinflammation and neurodegeneration?” Trends in Neurosciences, vol. 28, no. 9, pp. 487–493, 2005. View at: Publisher Site | Google Scholar
  13. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at: Publisher Site | Google Scholar
  14. J. S. De Olmos and W. R. Ingram, “An improved cupric-silver method for impregnation of axonal and terminal degeneration,” Brain Research, vol. 33, no. 2, pp. 523–529, 1971. View at: Publisher Site | Google Scholar
  15. H. J. G. Gundersen, T. F. Bendtsen, L. Korbo et al., “Some new, simple and efficient stereological methods and their use in pathological research and diagnosis,” APMIS, vol. 96, no. 5, pp. 379–394, 1988. View at: Publisher Site | Google Scholar
  16. B. D. Semple, K. Blomgren, K. Gimlin, D. M. Ferriero, and L. J. Noble-Haeusslein, “Brain development in rodents and humans: identifying benchmarks of maturation and vulnerability to injury across species,” Progress in Neurobiology, vol. 106-107, pp. 1–16, 2013. View at: Publisher Site | Google Scholar
  17. E. McClendon, K. Chen, X. Gong et al., “Prenatal cerebral ischemia triggers dysmaturation of caudate projection neurons,” Annals of Neurology, vol. 75, no. 4, pp. 508–524, 2014. View at: Publisher Site | Google Scholar
  18. V. B. Mountcastle, “The columnar organization of the neocortex,” Brain, vol. 120, part 4, pp. 701–722, 1997. View at: Publisher Site | Google Scholar
  19. Y.-H. Chen, T.-T. Kuo, M.-T. Chu, H.-I. Ma, Y.-H. Chiang, and E. Y.-K. Huang, “Postnatal systemic inflammation exacerbates impairment of hippocampal synaptic plasticity in an animal seizure model,” NeuroImmunomodulation, vol. 20, no. 4, pp. 223–232, 2013. View at: Publisher Site | Google Scholar
  20. A. E. Graf, K. M. Haines, C. R. Pierson et al., “Perinatal inflammation results in decreased oligodendrocyte numbers in adulthood,” Life Sciences, vol. 94, no. 2, pp. 164–171, 2014. View at: Publisher Site | Google Scholar
  21. T. Saito, H. Takahashi, H. Doken, H. Koyama, and Y. Aratani, “Phorbol myristate acetate induces neutrophil death through activation of p38 mitogen-activated protein kinase that requires endogenous reactive oxygen species other than HOCl,” Bioscience, Biotechnology and Biochemistry, vol. 69, no. 11, pp. 2207–2212, 2005. View at: Publisher Site | Google Scholar
  22. N. Suzuki, S. Suzuki, G. S. Duncan et al., “Severe impairment of interleukin-1 and toll-like receptor signalling in mice lacking IRAK-4,” Nature, vol. 416, no. 6882, pp. 750–754, 2002. View at: Publisher Site | Google Scholar
  23. N. Suzuki, S. Suzuki, U. Eriksson et al., “IL-1R-associated kinase 4 is required for lipopolysaccharide-induced activation of APC,” The Journal of Immunology, vol. 171, no. 11, pp. 6065–6071, 2003. View at: Publisher Site | Google Scholar
  24. Y.-F. Yang, Z. Chen, S.-L. Hu et al., “Interleukin-1 receptor associated kinases-1/4 inhibition protects against acute hypoxia/ischemia-induced neuronal injury in vivo and in vitro,” Neuroscience, vol. 196, pp. 25–34, 2011. View at: Publisher Site | Google Scholar
  25. M. Hedtjärn, A.-L. Leverin, K. Eriksson, K. Blomgren, C. Mallard, and H. Hagberg, “Interleukin-18 involvement in hypoxic-ischemic brain injury,” The Journal of Neuroscience, vol. 22, no. 14, pp. 5910–5919, 2002. View at: Google Scholar
  26. M. Hedtjärn, C. Mallard, Y. Iwakura, and H. Hagberg, “Combined deficiency of IL-1β18, but not IL-1αβ, reduces susceptibility to hypoxia-ischemia in the immature brain,” Developmental Neuroscience, vol. 27, no. 2–4, pp. 143–148, 2005. View at: Publisher Site | Google Scholar
  27. R. D. Wheeler, H. Boutin, O. Touzani, G. N. Luheshi, K. Takeda, and N. J. Rothwell, “No role for interleukin-18 in acute murine stroke-induced brain injury,” Journal of Cerebral Blood Flow and Metabolism, vol. 23, no. 5, pp. 531–535, 2003. View at: Google Scholar
  28. J. J. Volpe, “Systemic inflammation, oligodendroglial maturation, and the encephalopathy of prematurity,” Annals of Neurology, vol. 70, no. 4, pp. 525–529, 2011. View at: Publisher Site | Google Scholar

Copyright © 2015 Mark Dzietko et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

3303 Views | 514 Downloads | 4 Citations
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.